Evaluation of anti-hyperuricemic and nephroprotective activities and discovery of new XOD inhibitors of Morus alba L. root bark

文献类型： 外文期刊

第一作者： Wang, Yan-Ao

作者： Wang, Yan-Ao;Guo, Xu;Zhang, Meng-Qi;Sun, Shu-Tao;Ren, Qi-Dong;Wang, Mu-Xuan;Sun, Jin-Yue;Liu, Chao;Chen, Ying-Ying;Wang, Li-Na;Farag, Mohamed A.

作者机构：

关键词： Morus alba L. root bark; Hyperuricemia; Xanthine oxidase; Uric acid transporter; Nephroprotective; Bioactive phytocompounds

期刊名称：JOURNAL OF ETHNOPHARMACOLOGY （ 影响因子：5.4； 五年影响因子：5.4 ）

ISSN： 0378-8741

年卷期： 2025 年 343 卷

页码：

收录情况： SCI

摘要： Ethnopharmacological relevance: As a traditional Chinese medicine, Morus alba L. root bark (MAR) has diuretic and detumescent effects, which is used in prescriptions like Niaoduqing granules for hyperuricemia treatment. However, the anti-hyperuricemic and nephroprotective activities, underlying mechanism and material basis of MAR have not been reported. Aim of the study: This research aimed to explore the anti-hyperuricemic and nephroprotective activity and mechanism of MAR, along with the pursuit of potential xanthine oxidase (XOD) inhibitors within MAR. Materials and methods: XOD inhibitory assay and hyperuricemic mice model were employed to screen and estimate the active fraction of MAR. Then, active compositions were isolated and elucidated by diverse separation and spectroscopic techniques. The enzyme inhibition mechanism of the active compositions was investigated by enzyme kinetic and molecular docking. Results: The ethyl acetate fraction (MAR-EA) showed the strongest inhibitory activity against XOD. In hyperuricemic mice, MAR-EA decreased serum uric acid levels by suppressing XOD activity and modulating renal uric acid transporters (URAT1, GLUT9, ABCG2). Moreover, it alleviated hyperuricemia-induced kidney damage, which may be related to inhibiting the production of inflammatory factors. Noticeably, the combination of MAREA with allopurinol showed a synergistic effect. Meanwhile, a Diels-Alder adduct, albanol A (1) was isolated from MAR-EA with excellent XOD inhibition activity (IC50 = 0.116 mg/mL), which was categorized as a mixedtype XOD inhibitor. The molecular docking outcomes demonstrated that albanol A (1) exhibited a desirable interaction with XOD. Conclusion: This research supports MAR and albanol A as anti-hyperuricemic drug candidates, laying a foundation for further exploration.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序